Press Release PetVivo’s CTO Receives Award
Thursday, July 6, 2017
For Immediate Release:
PetVivo’s Dr. Masters Receives Award from Society for Biomaterials
PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on commercialization of innovative medical devices and therapeutics continues to receive recognition for its novel orthopedic devices. PetVivo’s Chief Technical Officer David B. Masters, Ph.D. has received the Star Abstract Award from the Orthopedics Biomaterials Special Interest Group, Society for Biomaterials. The award, which acknowledges significant advances in the field, recognizes abstracts that have an average abstract review score greater than or equal to 4.0 on a 1-5 scale.
Dr. Masters’ oral presentation of the award abstract is titled “Particles for Osteoarthritis Treatment: Injected Wet Particulate of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid Mechanically Cushion Joint with Long Duration”.
“It is an honor to be recognized by scientists in your field of study,” noted Dr. David Masters. “Leading biomaterial experts are increasingly recognizing the importance of incorporating natural biochemical components into their studied polymer biomaterials to help promote natural regeneration of tissue. We have been fortunate to be early adopters in utilizing collagen and its elastin-carbohydrate tissue counterparts to formulate a strong natural biomaterial matrix, allowing our company to carve out significant intellectual property around protein based device configurations that naturally help the body heal and protect itself.”
Dr. Masters also concludes: “Our MasterGel Hydrophilic Biomaterial (MHB) particles provide safe cushioning and lubricity to the joint, as well as a scaffolding that can help natural healing processes rebuild functional tissue. In this way, MHB particles alleviate the pain associated with missing and damaged cartilage to provide a protective environment in much the same way native cartilage protects the joint. Our MHB scaffolding imparts a chemical-structural feedback for natural cell-mediated responses, which allows implanted grafts and devices to integrate and/or regenerate endogenous tissues.
“For example, our biomaterial has been used in a number of tissue applications, including spinal disks, tissue glue, cosmetic dermal filler for skin wrinkle repair (clinicaltrials.gov NCT00414544), urinary sphincter muscle regeneration, blood vessel grafts and more, including over $5 million in National Institutes of Health funding. Indeed, we show that the current treatment for canine osteoarthritis, which relies on constant NSAID medication, can be eliminated for about a year following a single injection of MHB particles.” Dr. Masters’ complete abstract can be found here.
The MHB Particles are used in the production of PetVivo’s lead product, Kush™ Canine for the treatment of canine osteoarthritis. Kush Canine is scheduled for commercial launch later this year, followed shortly thereafter by Kush Equine for the treatment of lameness in horses. The particles used to make the Kush devices are part of a large pipeline of patented animal and human therapeutics developed and manufactured by Gel-Del® Technologies.
You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
PetVivo Holdings, Inc. routinely posts periodic reports and press releases that includes important information on our corporate website and/or Facebook page. Therefore, for more information please see us on Facebook and visit at our website at www.petvivo.com.
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.